Trials / Completed
CompletedNCT04676763
Substance P Challenge in Healthy Participants
An Open Label, Single Centre, Enabling Study to Investigate the Optimum Method for Use of Intradermal Substance P as a Challenge Agent in Healthy Participants
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The objectives of this enabling study are to characterize the wheal and flare responses over time following skin challenges with ascending concentrations of Substance P. This will be a 2-part study: Part 1 will aid in the understanding of the wheal and flare responses following Substance P. Part 2 will investigate the variability of the responses. Participants may be enrolled into Part 1 or Part 2, not both.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Substance P | Participants will receive Substance P |
| DRUG | Normal Saline | Participants will receive normal saline as Negative control |
| DRUG | Histamine | Participants will receive histamine as Positive control |
Timeline
- Start date
- 2021-03-02
- Primary completion
- 2021-07-21
- Completion
- 2021-07-21
- First posted
- 2020-12-21
- Last updated
- 2025-01-20
- Results posted
- 2024-02-08
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04676763. Inclusion in this directory is not an endorsement.